Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • Response Genetics sales and marketing update

    Response Genetics Inc. (NASDAQ:RGDX), Los Angeles, Calif. Business: Pharmacogenetics Response Genetics launched in the U.S. an expanded K-Ras (KRAS) assay which now covers mutations on exons 2, 3 and 4. The company's …

    Published on 3/17/2014
  • Roche sales and marketing update

    Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Diagnostic Roche launched the Elecsys Syphilis immunoassay diagnostic test in countries that recognize CE Mark approval to detect syphilis and screen donor …

    Published on 3/17/2014
  • Teva Pharmaceuticals Industries Ltd. sales and marketing update

    Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Business: Cancer Teva launched in the U.S. a generic version of Xeloda capecitabine from Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) for …

    Published on 3/17/2014
  • Cumberland, Astellas sales and marketing update

    Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), Nashville, Tenn. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Renal Cumberland acquired from Astellas U.S. rights to commercialize Vaprisol, a dual vasopressin…

    Published on 3/10/2014
  • Dara BioSciences, WellCare Health Plans Inc. sales and marketing update

    Dara BioSciences Inc. (NASDAQ:DARA), Raleigh, N.C. WellCare Health Plans Inc. (NYSE:WCG), Tampa, Fla. Business: Cancer Dara said managed care service provider WellCare will provide formulary status for Soltamox …

    Published on 3/10/2014
  • Diagnoplex, Unilabs sales and marketing update

    Diagnoplex S.A., Epalinges, Switzerland Unilabs S.A., Geneva, Switzerland Business: Diagnostic Unilabs launched Diagnoplex's Colox colon cancer screening test in Switzerland. The test can detect colorectal cancer from a…

    Published on 3/10/2014
  • Osmotica Pharmaceutical, Pernix Therapeutics sales and marketing update

    Osmotica Pharmaceutical Corp., Wilmington, N.C. Pernix Therapeutics Holdings Inc. (NASDAQ:PTX), The Woodlands, Texas Business: Neurology Osmotica granted Pernix U.S. commercialization rights to 50 and 100 mg Khedezla …

    Published on 3/10/2014
  • Teva sales and marketing update

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Business: Neurology Teva launched Adasuve loxapine in the U.S. to treat acute agitation in adults with schizophrenia or bipolar I disorder. The …

    Published on 3/10/2014
  • bioMerieux sales and marketing update

    bioMerieux S.A. (Euronext:BIM), Marcy l'Etoile, France Business: Diagnostic bioMerieux launched its Vidas C. difficile GDH immunoassay to diagnose Clostridium difficile infections. The test detects the enzyme glutamate …

    Published on 3/3/2014
  • Champions Oncology sales and marketing update

    Champions Oncology Inc. (OTCBB:CSBR), Hackensack, N.J. Business: Diagnostic Hospital network Parkway Cancer Centre will begin offering Champions Oncology's TumorGraft to cancer patients in Singapore and Southeast Asia. …

    Published on 3/3/2014
  • Kadmon, Valeant Pharmaceuticals sales and marketing update

    Kadmon Corp. LLC, New York, N.Y. Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX), Montreal, Quebec Business: Endocrine/Metabolic Valeant's Valeant Pharmaceuticals North America LLC subsidiary granted …

    Published on 3/3/2014
  • LabCorp, Thermo Fisher sales and marketing update

    Laboratory Corp. of America Holdings (NYSE:LH), Burlington, N.C. Thermo Fisher Scientific Inc. (NYSE:TMO), Waltham, Mass Business: Diagnostic LabCorp launched Thermo Fisher Scientific Inc.'s ImmunoCAP allergy tests for …

    Published on 3/3/2014
  • Qiagen sales and marketing update

    Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN), Venlo, the Netherlands Business: Diagnostic Qiagen launched the careHPV Test in India to detect high-risk HPV. The product is a test for 14 strains of HPV that does not require …

    Published on 3/3/2014
  • RedPath sales and marketing update

    RedPath Integrated Pathology Inc., Pittsburgh, Pa. Business: Diagnostic RedPath entered into a contract with preferred provider network MultiPlan Inc. (New York, N.Y.) to cover RedPath's PathFinder TG molecular …

    Published on 3/3/2014
  • Roche sales and marketing update

    Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Diagnostic Roche launched the automated CINtec PLUS cytology test in Europe, Asia, Latin America and Canada to detect pre-cancerous cervical disease. The test …

    Published on 3/3/2014
  • Takeda sales and marketing update

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Pharmaceuticals Takeda said it will realign its marketing system in Japan, effective April 1, so that each sales representative will be responsible for…

    Published on 3/3/2014
  • Teva sales and marketing update

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Business: Hematology Teva's Teva UK Ltd. subsidiary launched Lonquex lipegfilgrastim in the U.K. The product's price is 652.06 ($1,085.81) per 6 mg …

    Published on 3/3/2014
  • AOP Orphan, Cardiome sales and marketing update

    AOP Orphan Pharmaceuticals AG, Vienna, Austria Cardiome Pharma Corp. (TSX:COM; NASDAQ:CRME), Vancouver, B.C. Business: Cardiovascular Cardiome said IV Brinavess vernakalant for atrial fibrillation (AF) is now available …

    Published on 2/24/2014
  • Appistry, N-of-One sales and marketing update

    Appistry Inc., St. Louis, Mo. N-of-One, Waltham, Mass. Business: Bioinformatics, Pharmacogenetics Appistry and N-of-One partnered to jointly market N-of-One's molecular interpretation services together with Appistry's …

    Published on 2/24/2014
  • Biocept, J&J sales and marketing update

    Biocept Inc. (NASDAQ:BIOC), San Diego, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Diagnostic Medicare contractor Palmetto GBA LLC may not reimburse circulating tumor cell (CTC) assays for …

    Published on 2/24/2014
  • BioMarin sales and marketing update

    BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Novato, Calif. Business: Endocrine/Metabolic BioMarin disclosed the price of newly launched Vimizim elosulfase alfa, which FDA approved earlier in February to treat …

    Published on 2/24/2014
  • Forest Laboratories sales and marketing update

    Forest Laboratories Inc. (NYSE:FRX), New York, N.Y. Business: Neurology Forest said it would discontinue the sale of 5 and 10 mg tablets of Namenda memantine for Alzheimer's disease (AD), effective Aug. 15. Forest said …

    Published on 2/24/2014
  • Jazz Pharmaceuticals sales and marketing update

    Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Dublin, Ireland Business: Neurology Jazz launched Versacloz clozapine in the U.S. to treat severely ill treatment-resistant schizophrenia patients or those at risk of recurrent …

    Published on 2/24/2014
  • MDxHealth sales and marketing update

    MDxHealth S.A. (Euronext:MDXH), Liege, Belgium Business: Diagnostic MDxHealth said U.S. healthcare PPO network Prime Health Services Inc. will cover MDxHealth's ConfirmMDx for Prostate Cancer test. MDxHealth said the …

    Published on 2/24/2014
  • Pathway Genomics sales and marketing update

    Pathway Genomics Corp., San Diego, Calif. Business: Diagnostic Pathway Genomics launched its Hereditary Colorectal Cancer DNA Insight test to scan a patient's genome for conditions related to colorectal cancer, …

    Published on 2/24/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993